EOP2A Guidance Allows That Resource Constraints Might Block Meetings
This article was originally published in Pharmaceutical Approvals Monthly
FDA's final guidance on end-of-Phase 2A meetings codifies into policy the more realistic expectations of what the agency can handle in terms of meeting requests.
You may also be interested in...
Drug sponsors should use end-of-Phase 2A meetings for the in-depth discussions with FDA regarding dose estimation and selection that other pre-submission meetings do not allow for, according to a 1draft guidance
Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings